Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRDLCVE:NOTNYSE:NVONASDAQ:PYR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRDLCardiol Therapeutics$1.45-5.8%$1.26$0.77▼$2.63$127.28M1.04309,129 shs216,997 shsNOTNoront ResourcesC$1.10-0.5%C$1.09C$0.23▼C$1.11C$612.18MN/A512,544 shs68,388 shsNVONovo Nordisk A/S$69.31+0.2%$69.96$57.00▼$143.69$309.47B0.647.26 million shs7.31 million shsPYRPyroGenesis Canada$0.38$0.38$0.26▼$1.30$67.96M0.747,701 shs29,889 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRDLCardiol Therapeutics0.00%+7.52%+7.52%+78.35%-23.43%NOTNoront Resources0.00%0.00%0.00%0.00%0.00%NVONovo Nordisk A/S0.00%+0.80%-7.56%+8.71%-51.50%PYRPyroGenesis Canada0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRDLCardiol Therapeutics1.8743 of 5 stars3.73.00.00.00.60.00.6NOTNoront ResourcesN/AN/AN/AN/AN/AN/AN/AN/ANVONovo Nordisk A/S4.7005 of 5 stars4.15.02.50.02.40.03.1PYRPyroGenesis CanadaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRDLCardiol Therapeutics 3.33Buy$8.00451.72% UpsideNOTNoront Resources 0.00N/AN/AN/ANVONovo Nordisk A/S 2.27Hold$112.0061.59% UpsidePYRPyroGenesis Canada 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CRDL, NOT, PYR, and NVO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025CRDLCardiol TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$9.004/28/2025NVONovo Nordisk A/SHsbc Global ResSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/25/2025NVONovo Nordisk A/SDbs BankSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeSell4/17/2025NVONovo Nordisk A/SGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/17/2025NVONovo Nordisk A/SBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$105.00 ➝ $64.004/16/2025CRDLCardiol TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.004/15/2025NVONovo Nordisk A/SBNP ParibasSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageStrong-Buy ➝ Underperform4/7/2025CRDLCardiol TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRDLCardiol TherapeuticsN/AN/AN/AN/A$0.22 per shareN/ANOTNoront ResourcesN/AN/AC$0.01 per share84.23C($0.03) per shareN/ANVONovo Nordisk A/S$42.12B7.35$3.91 per share17.73$4.66 per share14.87PYRPyroGenesis Canada$14.63M4.65N/AN/A$0.07 per share5.43Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRDLCardiol Therapeutics-$26.77M-$0.34N/AN/AN/AN/A-209.63%-141.09%7/14/2025 (Estimated)NOTNoront ResourcesN/A-C$0.15N/A∞N/AN/AN/AN/AN/ANVONovo Nordisk A/S$14.64B$3.3820.5114.871.3534.52%80.94%24.23%8/6/2025 (Estimated)PYRPyroGenesis Canada-$24.74M-$0.11N/A∞N/A-233.18%-194.66%-68.91%N/ALatest CRDL, NOT, PYR, and NVO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025NVONovo Nordisk A/S$0.92$0.92N/A$0.92N/A$11.87 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRDLCardiol TherapeuticsN/AN/AN/AN/AN/ANOTNoront ResourcesN/AN/AN/AN/AN/ANVONovo Nordisk A/S$1.642.37%N/A48.52%N/APYRPyroGenesis CanadaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRDLCardiol Therapeutics0.013.263.26NOTNoront ResourcesN/A0.160.15NVONovo Nordisk A/S0.700.740.56PYRPyroGenesis Canada0.260.860.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRDLCardiol Therapeutics12.49%NOTNoront ResourcesN/ANVONovo Nordisk A/S11.54%PYRPyroGenesis Canada0.41%Insider OwnershipCompanyInsider OwnershipCRDLCardiol Therapeutics5.25%NOTNoront ResourcesN/ANVONovo Nordisk A/S0.07%PYRPyroGenesis Canada47.68%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRDLCardiol Therapeutics2082.65 million78.31 millionNot OptionableNOTNoront Resources101,700559.07 millionN/ANot OptionableNVONovo Nordisk A/S77,3494.47 billion4.46 billionOptionablePYRPyroGenesis Canada2,020178.88 million93.59 millionNot OptionableCRDL, NOT, PYR, and NVO HeadlinesRecent News About These CompaniesPyroGenesis Inc.: PyroGenesis Reports Voting Results from 2025 Annual Meeting of ShareholdersJune 28, 2025 | finanznachrichten.dePyroGenesis: Top 10 Undervalued Industrial Products Industry Stocks (PYR)June 14, 2025 | theglobeandmail.comPyroGenesis achieves approved supplier status with Boeing for titanium AM powdersMay 30, 2025 | voxelmatters.comVBuzz on the Bullboards: Bombardier vs Boeing, MediPharm “under attack”May 29, 2025 | msn.comEarnings call transcript: PyroGenesis Q4 2024 sees strong revenue growthApril 3, 2025 | uk.investing.comPyroGenesis Full Year 2024 Earnings: CA$0.04 loss per share (vs CA$0.16 loss in FY 2023)April 3, 2025 | finance.yahoo.comEquity Markets Mixed as Canada Trade Tensions SimmerMarch 11, 2025 | msn.comPyroGenesis successfully operates fumed silica reactor pilot plantFebruary 27, 2025 | canadianmanufacturing.comCBuzz on the Bullboards: No tariffs? No problem!February 6, 2025 | msn.comPyroGenesis Inc.: PyroGenesis Provides Update on Impact of Potential U.S. TariffsFebruary 6, 2025 | finanznachrichten.dePyroGenesis receives $1.85M under Drosrite contractJanuary 21, 2025 | canadianmanufacturing.comCFederal government invests in Cdn. technologies to support clean fuelsJanuary 8, 2025 | canadianmanufacturing.comCGovernment invests $11M in Canadian technologies to advance clean fuelsJanuary 8, 2025 | plant.caPPyroGenesis Canada Tackles PFAS with Plasma TechnologyDecember 4, 2024 | markets.businessinsider.comBuzz on the Bullboards: Stocks to watch in volatile times.November 28, 2024 | msn.comPyroGenesis Canada Optimistic About U.S. Policy ChangesNovember 20, 2024 | markets.businessinsider.comPyroGenesis Partners with Global Steel GiantNovember 20, 2024 | markets.businessinsider.comStocks in play: PyroGenesis Inc.November 12, 2024 | ca.finance.yahoo.comPyroGenesis Inc. Rebrands and Relocates HeadquartersNovember 12, 2024 | markets.businessinsider.comPyroGenesis Canada Third Quarter 2024 Earnings: CA$0.02 loss per share (vs CA$0.035 loss in 3Q 2023)November 9, 2024 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 AI Infrastructure Stocks With Strong Growth, Not HypeBy Chris Markoch | June 26, 2025View 3 AI Infrastructure Stocks With Strong Growth, Not HypeSoundHound’s AI Growth Story Is Just Getting StartedBy Gabriel Osorio-Mazilli | June 16, 2025View SoundHound’s AI Growth Story Is Just Getting Started3 Notable Stocks Just Split: Which One Could Be the Big Winner?By Leo Miller | June 26, 2025View 3 Notable Stocks Just Split: Which One Could Be the Big Winner?Top 5 Stocks for July: Momentum-Driven Picks to Watch NowBy Thomas Hughes | June 30, 2025View Top 5 Stocks for July: Momentum-Driven Picks to Watch NowAnalyst Sees Meta Hitting $800: What May Lead Shares to New HighsBy Leo Miller | June 24, 2025View Analyst Sees Meta Hitting $800: What May Lead Shares to New HighsCRDL, NOT, PYR, and NVO Company DescriptionsCardiol Therapeutics NASDAQ:CRDL$1.45 -0.09 (-5.84%) Closing price 04:00 PM EasternExtended Trading$1.46 +0.01 (+0.55%) As of 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.Noront Resources CVE:NOTC$1.10 -0.01 (-0.45%) As of 04/6/2022Noront Resources Ltd., a resource company, engages in the acquisition, development, and exploration of base and precious metals in Canada. It explores for nickel, copper, zinc, platinum group metals, chromite, iron, titanium, vanadium, gold, and silver. The company's flagship property is the Eagle's Nest project located in the James Bay Lowlands, Ontario. The company was formerly known as White Wing Resources Inc. and changed its name to Noront Resources Ltd. in July 1983. Noront Resources Ltd. was incorporated in 1980 and is headquartered in Toronto, Canada.Novo Nordisk A/S NYSE:NVO$69.31 +0.14 (+0.20%) Closing price 03:59 PM EasternExtended Trading$69.32 +0.02 (+0.02%) As of 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.PyroGenesis Canada NASDAQ:PYRPyroGenesis Canada Inc. designs, develops, manufactures, and commercializes plasma processes and solutions worldwide. It offers DROSRITE, a process for enhancing metal recovery from dross without any hazardous by-products; plasma atomization process that allows produce and sell high purity spherical metal powders; PUREVAP, a process to produce high purity metallurgical and solar grade silicon from quartz; and PUREVAP NSiR, which is designed to transform silicon into spherical silicon nano powders and nanowires for use in lithium-ion batteries. The company also provides plasma torches and plasma torch systems used toreplace fossil fuel burners in industrial iron ore pelletization process; plasma arc waste destruction systems for waste destruction onboard ships; steam plasma arc refrigerant cracking systems for the destruction of certain refrigerants, including chlorofluorocarbons, hydrofluorocarbons, and hydrochlorofluorocarbons; plasma arc chemical warfare agent destruction systems, which are mobile platforms for the onsite destruction of chemical warfare agents; plasma resource recovery systems for land-based waste destruction and waste-to-energy applications; plasma torches for waste gasification and combustion; and plasma arc gasification and vitrification. In addition, it offers engineering and manufacturing expertise, and contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (including 3D printing), oil and gas, and environmental industries. Further, the company provides installation, commissioning, and start-up services. PyroGenesis Canada Inc. is headquartered in Montréal, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron Insiders Sell But Investors Should Buy, Buy, Buy Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up ExxonMobil: Limited Risk and Lots of Reward With This Oil Play D-Wave Is Rising Again Despite Dilution—What’s the Deal? Datadog Joins S&P 500, Triggering a New Wave of Upside MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
